ReWalk Robotics Reports Fourth Quarter and Year-End 2014 Financial Results Fourth Quarter Revenue Up 283% Year-Over-Year to $1.5 Million YOKNEAM ILIT, Israel and

ReWalk Robotics Reports Fourth Quarter

and Year-End 2014 Financial Results

Fourth Quarter Revenue Up 283% Year-Over-Year

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk," or "the Company") today announced its financial

results for the three- and twelve-month periods ended December 31, 2014. Highlights of and subsequent to the fourth quarter 2014

"2014 was a landmark year for ReWalk

highlighted by two significant events. We gained FDA clearance for our ReWalk System as the only powered exoskeleton that can

be legally marketed in the United States. We are excited to be able to provide wheelchair-bound individuals with access to the

ReWalk system for daily use at home and in their communities, where they need it most," said Larry Jasinski, Chief Executive

Officer. "Additionally, we significantly strengthened the Company's balance sheet through our successful initial public

offering, increasing our financial flexibility."

"We continue to secure reimbursement on a case-by-case

basis for ReWalk personal systems in the U.S. and Germany, and are building our infrastructure to support our ongoing growth. This

included expanding our reimbursement team, which assists qualified individuals in obtaining payment for their systems, as well

as our clinical training and service personnel."

"We expect our ongoing investment in training centers

around the world will support ReWalk's growing international footprint and serve as a solid channel for placing more personal

systems in the homes of ReWalkers. We will continue to aggressively execute our strategy across all of our markets to build value

for our shareholders and customers alike," Jasinski concluded.

Fourth Quarter 2014 Financial

Total revenue was $1.5 million for

the fourth quarter of 2014, up 283% compared with $0.4 million in the fourth quarter of 2013, due to higher placements of ReWalk

systems during the fourth quarter of 2014. In the fourth quarter of 2014, 31 ReWalk systems were placed compared with six ReWalk

systems placed in the prior year period.

Gross loss for the fourth quarter

of 2014 was $0.5 million as compared to a gross loss of $0.1 million in the fourth quarter of 2013. This was largely due to a

one-time expense relating to the early repayment, at a discount, of a royalty-bearing grant to the BIRD Foundation of $0.5

million during the fourth quarter of 2014, which will improve gross margins in 2015. Margins were also impacted by lower

average selling prices outside of the U.S. related to specific efforts to seed training centers in select markets as

we expand our geographic footprint.

Total operating expenses in the fourth

quarter of 2014 were $4.8 million, compared with $2.6 million in the fourth quarter of 2013, and reflects the Company's increased

investment in sales, marketing, and research and development resources and the increased cost of being a publicly-traded company.

Net loss was $5.5 million for the fourth

quarter of 2014 compared with $3.5 million in the prior year quarter. Non-GAAP net loss, excluding expenses relating to the aforementioned

repayment of the BIRD Foundation grant and non-cash stock based compensation expenses, for the fourth quarter of 2014 was $4.6

million compared with non-GAAP net loss of $2.7 million in the prior year quarter.

A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

Year-End 2014 Financial Highlights

Total revenues were $4.0 million for

the year ended December 31, 2014, up 149% compared with $1.6 million during the year ended December 31, 2013, due to higher placements

of ReWalk systems during the 2014 period. In 2014, 74 ReWalk systems were placed compared with 25 ReWalk systems placed during

Gross loss was $0.6 million for the

year ended December 31, 2014, as compared to a gross loss of $0.4 million for the prior year, reflecting the aforementioned repayment

of the Bird Foundation grant partially offset by the positive impact of transitioning manufacturing activities of the ReWalk systems

Total operating expenses in fiscal

2014 were $19.3 million, compared with $8.3 million in the prior year period. The increase reflects the Company's increased

investment in sales, marketing, and research and development resources as well as the increased cost of being a publicly-traded

Net loss for the year ended December

31, 2014 was $21.7 million compared with $12.2 million during the year ended December 31, 2013. Non-GAAP net loss excluding expenses

relating to the early repayment, at a discount, of the BIRD Foundation grant and non-cash stock based compensation expenses, was

$14.7 million for the year ended December 31, 2014, compared with non-GAAP net loss of $8.7 million during the year ended December

A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

As of December 31, 2014, ReWalk had

$43.5 million in cash and cash equivalents and short-term deposits versus a total of $47.7 million at the end of Q3 2014. During

the twelve months ended December 31, 2014, the Company raised $36.3 million, net, from its initial public offering, $12.8 million

from an equity investment round, and $1.1 million from the exercise of warrants to purchase convertible preferred shares.

ReWalk management will host its third

quarter conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 77059924.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally

change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the

U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

Forward Looking Statements

This press release contains forward-looking

information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking

statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"

"will," "may," "intends," "anticipate(s)," "look forward," "upcoming,"

"plan," "enables," "potentially," "entitles," and similar expressions are intended

to identify forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated

revenues and underlying sales for the fourth quarter of 2014; future availability of reimbursement for ReWalk in Germany and the

United States; and the successful and timely achievement of favorable coverage decisions for ReWalk by additional major insurers.

All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond

the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected

by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to the following:

the market for medical exoskeletons is new and unproven, and important assumptions about the potential market for our products

may be inaccurate; the Company has a limited operating history upon which you can evaluate our business plan and prospects; if

we are unable to expand our sales, marketing and training infrastructure, we may fail to increase our sales; the health benefits

of ReWalk have not been substantiated by long-term clinical data, which could limit sales; the Company may fail to secure or retain

adequate coverage or reimbursement for ReWalk by third-party payors; the Company depends on a single third-party to manufacture

ReWalk and a limited number of third-party suppliers for certain components of ReWalk; the Company's future growth and operating

results will depend on our ability to develop and commercialize new products and penetrate new markets; the Company operates in

a competitive industry that is subject to rapid technological change, and we expect competition to increase; and the Company is

subject to extensive governmental regulations relating to the manufacturing, labeling and marketing of our products. These

and other risk factors are set forth in the Company's final prospectus filed with the Securities and Exchange Commission

on September 15, 2014, and our other reports filed from time to time with the Securities and Exchange Commission. Readers

are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. ReWalk

does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after

the date hereof, or to reflect the occurrence of or non-occurrence of any events.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are